The blockade of IL-8 signaling with ladarixin (an allosteric inhibitor of CXCR1 and CXCR2) and, even more strikingly, its combination with tocilizumab (an anti-IL-6 receptor antibody) reduced lung metastasis formation in a xenograft mouse model of osteosarcoma and, notably, prevented the occurrence of MSC-induced tumor resistance to antimetastatic drugs (abstract submitted to the ASCO 2022 meeting). This evidence concerns the gene CXCL8 and osteosarcoma.